Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographics for OMT patients in Norway (1997-2003) (n = 3221)

From: A day-by-day investigation of changes in criminal convictions before and after entering and leaving opioid maintenance treatment: a national cohort study

Characteristics of patients and treatment episodes All patients Male Female P-valuea
Patients (n, %) 3221 (100) 2176 (67.6) 1045 (32.4)  
Age at treatment start (mean, SD) 37.0 (6.7) 37.7 (6.6) 35.5 (6.6) < 0.001
Age groups (n, %)
< 30 450 (14.0) 254 (11.7) 196 (18.8) < 0.001
30-40 1797 (55.8) 1185 (54.5) 612 (58.6) < 0.001
> 40 974 (30.2) 737 (33.9) 237 (22.7) < 0.001
Continuous treatment (n, %) 2046 (63.5) 1391 (63.9) 655 (62.7) 0.492
Dropout (n, %) 1175 (36.5) 785 (36.1) 390 (37.3) 0.492
1 treatment episode 660 (20.5) 440 (20.2) 220 (21.1) 0.584
2 treatment episodes 434 (13.5) 294 (13.5) 140 (13.4) 0.929
3+ treatment episodes 81 (2.5) 51 (2.3) 30 (2.3) 0.371
Months in waiting-list, (median, SD) 5.30 (11.78) 5.49 (11.84) 4.90 (11.65) 0.099
Years in treatment, continuous (median, SD) 1.97 (1.52) 1.94 (1.52) 2.05 (1.55) 0.059
Years in treatment, drop out (median, SD) 1.26 (1.28) 1.22 (1.21) 1.36 (1.39) < 0.05
Months between treatment (median, range) b 2.7 (0-51.9) 3.2 (0-51.9) 2.4 (0-50) 0.187
Months after treatment (median, range) c 13.1 (0-58.9) 13.1 (0.2-58.9) 13.2 (0-50.5) 0.791
  1. aP-value for gender difference. bBetween treatment period: sum of months between treatment episodes. cThe post-treatment period: sum of months after ending treatment.